Neovasc Inc (US) (NASDAQ:NVCN) (TSE:NVC) was down 7% on Friday . The stock traded as low as $0.52 and last traded at $0.53. Approximately 964,460 shares were traded during trading, an increase of 21% from the average daily volume of 794,962 shares. The stock had previously closed at $0.57.

Several equities research analysts recently weighed in on NVCN shares. ValuEngine downgraded shares of Neovasc Inc (US) from a “sell” rating to a “strong sell” rating in a research note on Friday, December 1st. Zacks Investment Research raised shares of Neovasc Inc (US) from a “hold” rating to a “buy” rating and set a $1.75 target price on the stock in a research note on Wednesday, October 11th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus target price of $3.58.

The firm has a market capitalization of $58.00, a PE ratio of 1.98 and a beta of 1.48.

A hedge fund recently bought a new stake in Neovasc Inc (US) stock. Virtu KCG Holdings LLC acquired a new stake in Neovasc Inc (US) (NASDAQ:NVCN) (TSE:NVC) during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 108,132 shares of the medical equipment provider’s stock, valued at approximately $149,000. Virtu KCG Holdings LLC owned about 0.14% of Neovasc Inc (US) at the end of the most recent quarter. Institutional investors and hedge funds own 19.04% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This piece of content was posted by Daily Political and is the sole property of of Daily Political. If you are viewing this piece of content on another publication, it was stolen and republished in violation of US & international copyright & trademark law. The original version of this piece of content can be viewed at

About Neovasc Inc (US)

Neovasc Inc (Neovasc) is a specialty medical device company. The Company develops, manufactures and markets products for the cardiovascular marketplace. The Company’s segment is the development, manufacture and marketing of medical devices. Its products include the Tiara technology in development for the transcatheter treatment of mitral valve disease, the Neovasc Reducer for the treatment of refractory angina, and tissue products.

Receive News & Ratings for Neovasc Inc (US) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neovasc Inc (US) and related companies with's FREE daily email newsletter.